Investment Analysts’ Weekly Ratings Updates for Medexus Pharmaceuticals (MDP)

A number of firms have modified their ratings and price targets on shares of Medexus Pharmaceuticals (TSE: MDP) recently:

• 1/22/2025 – Medexus Pharmaceuticals was upgraded by analysts at Leede Financial from a “moderate buy” rating to a “strong-buy” rating.
• 1/17/2025 – Medexus Pharmaceuticals was upgraded by analysts at Ventum Cap Mkts to a “strong-buy” rating.
• 1/14/2025 – Medexus Pharmaceuticals had its price target raised by analysts at Stifel Nicolaus from C$4.15 to C$4.50.
• 1/8/2025 – Medexus Pharmaceuticals was upgraded by analysts at Raymond James from an “outperform” rating to a “strong-buy” rating. They now have a C$4.00 price target on the stock.
• 12/23/2024 – Medexus Pharmaceuticals was upgraded by analysts at Alliance Global Partners to a “strong-buy” rating.

Medexus Pharmaceuticals Stock Up 10.1 %

TSE MDP opened at C$4.92 on Monday. The company has a market cap of C$120.69 million, a price-to-earnings ratio of 98.40 and a beta of 1.96. Medexus Pharmaceuticals Inc. has a 52 week low of C$1.47 and a 52 week high of C$5.56. The business has a 50 day moving average price of C$3.25 and a 200-day moving average price of C$2.72.

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.